228 INTERIM RESULTS OF AN OPEN-LABEL EXTENSION STUDY OF ANTOLIMAB, AN ANTI-SIGLEC-8 ANTIBODY, FOR THE TREATMENT OF PATIENTS WITH EOSINOPHILIC GASTRITIS AND/OR EOSINOPHILIC ENTERITIS